Preliminary research on LncRNA ATP2B2-IT2 in neovascularization of diabetic retinopathy.
Diabetic Retinopathy
/ genetics
RNA, Long Noncoding
/ genetics
Humans
Cell Proliferation
Cell Movement
Vascular Endothelial Growth Factor A
/ metabolism
Cells, Cultured
Retinal Neovascularization
/ genetics
Retinal Vessels
/ metabolism
Gene Expression Regulation
Endothelial Cells
/ metabolism
Neovascularization, Pathologic
/ genetics
Diabetic retinopathy
LncRNA ATP2B2-IT2
Migration
Neovascularization
Proliferation
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
21 Jun 2024
21 Jun 2024
Historique:
received:
17
09
2023
accepted:
12
06
2024
medline:
22
6
2024
pubmed:
22
6
2024
entrez:
21
6
2024
Statut:
epublish
Résumé
Diabetic retinopathy (DR) is a common complication of diabetes, and recent findings have shown that long noncoding RNAs (lncRNAs) may be involved in its pathogenesis. Through bioinformatics analysis, we found that lncRNA ATP2B2-IT2 may be involved in this process. This study primarily investigated the expression of the lncRNA ATP2B2-IT2 in human retinal microvascular endothelial cells (HRMECs) under high-glucose conditions and its effects on HRMEC proliferation, migration, and neovascularization. We used RT‒PCR to assess the expression levels of lncRNA ATP2B2-IT2 and vascular endothelial growth factor (VEGF) in HRMECs under normal glucose (5.5 mmol/L) and high glucose (30 mmol/L) conditions. HRMECs were subsequently divided into four groups: the normal glucose (NG), high glucose (HG), high glucose with lncRNA ATP2B2-IT2 silencing (HG + si-lncRNA ATP2B2-IT2), and high glucose with silencing control (HG + si-NC) groups. The expression levels of the lncRNA ATP2B2-IT2 and VEGF in each group were determined using RT‒PCR. Thereafter, cell proliferation, migration, and neovascularization were assessed using CCK-8, Transwell, and tube formation assays, respectively. RT‒PCR revealed that the expression levels of the lncRNA ATP2B2-IT2 and VEGF were greater in the HG group than in the NG group (P < 0.05). After silencing of the lncRNA ATP2B2-IT2, the expression of VEGF decreased significantly (P < 0.05). Subsequent CCK-8, Transwell, and tube formation assays demonstrated that compared to those in the NG group, the HRMECs in the HG group exhibited significantly increased proliferation, migration, and neovascularization (P < 0.05). However, after silencing of the lncRNA ATP2B2-IT2, the proliferation, migration, and neovascularization of HRMECs were significantly decreased in the HG + si-lncRNA ATP2B2-IT2 group compared to those in the HG group (P < 0.05). LncRNA ATP2B2-IT2 may promote the proliferation, migration and neovascularization of HRMECs under high-glucose conditions.
Identifiants
pubmed: 38907191
doi: 10.1186/s12886-024-03523-5
pii: 10.1186/s12886-024-03523-5
doi:
Substances chimiques
RNA, Long Noncoding
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
267Subventions
Organisme : National Nature Science Foundation of China
ID : 82160200
Organisme : R&D Program of The First People's Hospital of Zunyi
ID : [No.(2020)4
Organisme : Science and Technology Fund Project of Guizhou Provincial Health Commission in 2020
ID : gzwjk2020-1-155
Organisme : Science and Technology Planning Project of Zunyi
ID : No.HZ(2022)58
Informations de copyright
© 2024. The Author(s).
Références
Fralick M, Jenkins AJ, Khunti K, Mbanya JC, Mohan V, Schmidt MI. Global accessibility of therapeutics for diabetes mellitus. Nat Rev Endocrinol. 2022;18(4):199–204.
doi: 10.1038/s41574-021-00621-y
pubmed: 35039662
pmcid: 8762447
van Sloten TT, Sedaghat S, Carnethon MR, Launer LJ, Stehouwer C. Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. Lancet Diabetes Endocrinol. 2020;8(4):325–36.
doi: 10.1016/S2213-8587(19)30405-X
pubmed: 32135131
pmcid: 11044807
Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2suppl):25–32.
doi: 10.1177/2047487319878371
pubmed: 31722562
Cardoso C, Leite NC, Salles GF. Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: the Rio De Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2020;19(1):50.
doi: 10.1186/s12933-020-01030-7
pubmed: 32359350
pmcid: 7196231
Mansour A, Mousa M, Abdelmannan D, Tay G, Hassoun A, Alsafar H. Microvascular and macrovascular complications of type 2 diabetes mellitus: Exome wide association analyses. Front Endocrinol (Lausanne). 2023;14:1143067.
doi: 10.3389/fendo.2023.1143067
pubmed: 37033211
Zhang B, Chou Y, Zhao X, Yang J, Chen Y. Early detection of microvascular impairments with Optical Coherence Tomography Angiography in Diabetic patients without clinical retinopathy: a Meta-analysis. Am J Ophthalmol. 2021;222:226–37.
doi: 10.1016/j.ajo.2020.09.032
pubmed: 32976846
Middel CS, Hammes HP, Kroll J. Advancing Diabetic Retinopathy Research: analysis of the neurovascular unit in zebrafish. Cells. 2021. 10(6).
Flaxel CJ, Adelman RA, Bailey ST, et al. Diabet Retinopathy Preferred Pract Pattern® Ophthalmol. 2020;127(1):P66–145.
Danek D, Larsen B, Anderson-Nelson S. Non-proliferative diabetic retinopathy. Dis Mon. 2021;67(5):101139.
doi: 10.1016/j.disamonth.2021.101139
pubmed: 33541706
Tomita Y, Cagnone G, Fu Z, et al. Vitreous metabolomics profiling of proliferative diabetic retinopathy. Diabetologia. 2021;64(1):70–82.
doi: 10.1007/s00125-020-05309-y
pubmed: 33099660
Leley SP, Ciulla TA, Bhatwadekar AD. Diabetic Retinopathy in the Aging Population: a perspective of Pathogenesis and Treatment. Clin Interv Aging. 2021;16:1367–78.
doi: 10.2147/CIA.S297494
pubmed: 34290499
pmcid: 8289197
Schreur V, Brouwers J, Van Huet R, et al. Long-term outcomes of vitrectomy for proliferative diabetic retinopathy. Acta Ophthalmol. 2021;99(1):83–9.
doi: 10.1111/aos.14482
pubmed: 32643273
Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377–90.
doi: 10.1038/s41581-020-0278-5
pubmed: 32398868
pmcid: 9639302
The Prevention of Diabetes Mellitus. JAMA. 2021;325(2):190.
doi: 10.1001/jama.2020.17738
Magliano DJ, Boyko EJ. IDF DIABETES ATLAS. Brussels; 2021.
Wan P, Su W, Zhang Y, et al. LncRNA H19 initiates microglial pyroptosis and neuronal death in retinal ischemia/reperfusion injury. Cell Death Differ. 2020;27(1):176–91.
doi: 10.1038/s41418-019-0351-4
pubmed: 31127201
Radhakrishnan R, Kowluru RA. Long noncoding RNA MALAT1 and regulation of the antioxidant Defense System in Diabetic Retinopathy. Diabetes. 2021;70(1):227–39.
doi: 10.2337/db20-0375
pubmed: 33051272
Zeng L, Zhou M, Wang X, et al. Aberrant lncRNA expression in patients with proliferative diabetic retinopathy: preliminary results from a single-center observational study. BMC Ophthalmol. 2023;23(1):94.
doi: 10.1186/s12886-023-02817-4
pubmed: 36899334
pmcid: 9999565
Crabtree GS, Chang JS. Management of complications and vision loss from proliferative Diabetic Retinopathy. Curr Diab Rep. 2021;21(9):33.
doi: 10.1007/s11892-021-01396-2
pubmed: 34477996
Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176(6):1248–64.
doi: 10.1016/j.cell.2019.01.021
pubmed: 30849371
pmcid: 6410740
Simó R, Hernández C. New insights into Treating Early and Advanced Stage Diabetic Retinopathy. Int J Mol Sci. 2022. 23(15).
Ahmad A, Nawaz MI. Molecular mechanism of VEGF and its role in pathological angiogenesis. J Cell Biochem. 2022;123(12):1938–65.
doi: 10.1002/jcb.30344
pubmed: 36288574
Uemura A, Fruttiger M, D’Amore PA, et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res. 2021;84:100954.
doi: 10.1016/j.preteyeres.2021.100954
pubmed: 33640465
pmcid: 8385046
Bourhis M, Palle J, Galy-Fauroux I, Terme M. Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment. Front Immunol. 2021;12:616837.
doi: 10.3389/fimmu.2021.616837
pubmed: 33854498
pmcid: 8039365
Geng M, Liu W, Li J, et al. LncRNA as a regulator in the development of diabetic complications. Front Endocrinol (Lausanne). 2024;15:1324393.
doi: 10.3389/fendo.2024.1324393
pubmed: 38390204